Affordable Access

Publisher Website

Left ventricular heart failure and pulmonary hypertension.

  • Rosenkranz, Stephan1
  • Gibbs, J Simon R2
  • Wachter, Rolf3
  • De Marco, Teresa4
  • Vonk-Noordegraaf, Anton5
  • Vachiéry, Jean-Luc6
  • 1 Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln, Kerpener Str. 62, 50937 Köln, Germany Cologne Cardiovascular Research Center (CCRC), Universität zu Köln, Köln, Germany [email protected] , (Germany)
  • 2 National Heart and Lung Institute (NHLI), Imperial College London, London, UK Department of Cardiology, National Pulmonary Hypertension Service, Hammersmith Hospital London, London, UK.
  • 3 Klinik für Kardiologie und Pneumologie, Herzzentrum, Georg-August-Universität, Universitätsmedizin Göttingen, Göttingen, Germany German Cardiovascular Research Center (DZHK), Göttingen, Germany. , (Germany)
  • 4 Division of Cardiology, University of California San Francisco (UCSF), San Francisco, CA, USA.
  • 5 Department of Pneumology, VU University Medical Center, Amsterdam, The Netherlands. , (Netherlands)
  • 6 Department of Cardiology, Hopital Erasme, Université Libre de Bruxelles, Brussels, Belgium. , (Belgium)
Published Article
European Heart Journal
Oxford University Press
Publication Date
Mar 21, 2016
DOI: 10.1093/eurheartj/ehv512
PMID: 26508169


In patients with left ventricular heart failure (HF), the development of pulmonary hypertension (PH) and right ventricular (RV) dysfunction are frequent and have important impact on disease progression, morbidity, and mortality, and therefore warrant clinical attention. Pulmonary hypertension related to left heart disease (LHD) by far represents the most common form of PH, accounting for 65-80% of cases. The proper distinction between pulmonary arterial hypertension and PH-LHD may be challenging, yet it has direct therapeutic consequences. Despite recent advances in the pathophysiological understanding and clinical assessment, and adjustments in the haemodynamic definitions and classification of PH-LHD, the haemodynamic interrelations in combined post- and pre-capillary PH are complex, definitions and prognostic significance of haemodynamic variables characterizing the degree of pre-capillary PH in LHD remain suboptimal, and there are currently no evidence-based recommendations for the management of PH-LHD. Here, we highlight the prevalence and significance of PH and RV dysfunction in patients with both HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), and provide insights into the complex pathophysiology of cardiopulmonary interaction in LHD, which may lead to the evolution from a 'left ventricular phenotype' to a 'right ventricular phenotype' across the natural history of HF. Furthermore, we propose to better define the individual phenotype of PH by integrating the clinical context, non-invasive assessment, and invasive haemodynamic variables in a structured diagnostic work-up. Finally, we challenge current definitions and diagnostic short falls, and discuss gaps in evidence, therapeutic options and the necessity for future developments in this context. © The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology.

Report this publication


Seen <100 times